Palladin Antibody (1E6)

Immunocytochemistry/ Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959]

Immunocytochemistry/Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959] - Immunofluorescence on a7r5 cells.

Western Blot: Palladin Antibody (1E6) [NBP1-25959]

Western Blot: Palladin Antibody (1E6) [NBP1-25959] - Western blot analysis of HeLa (A), A431 (B), NIH3T3 (C), and PC-12 (D) cell line extracts using Palladin antibody at 1ug/ml.

Immunohistochemistry-Paraffin: Palladin Antibody (1E6) [NBP1-25959]

Immunohistochemistry-Paraffin: Palladin Antibody (1E6) [NBP1-25959] - Palladin was detected in immersion fixed paraffin-embedded sections of human heart using Mouse Anti-Human Palladin (1E6) Monoclonal Antibody (Catalog # NBP1-25959) at 1:100 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm in cardiomyocytes.

Flow Cytometry: Palladin Antibody (1E6) [NBP1-25959]

Flow Cytometry: Palladin Antibody (1E6) [NBP1-25959] - An intracellular stain was performed on HeLa cells with Palladin Antibody [1E6] NBP1-25959AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.

Immunohistochemistry: Palladin Antibody (1E6) [NBP1-25959] -

Immunohistochemistry: Palladin Antibody (1E6) [NBP1-25959] - Palladin staining of paraffin-embedded patient tissues.A. IHC staining was performed using standard antigen-retrieval protocols, & counter-stained with hematoxylin. Tissue sections were stained for palladin using two palladin antibodies: polyclonal 622 & monoclonal 1E6. Palladin stain is detected with brown reaction product. In tumor sections, palladin is detected at dramatically elevated levels in the stromal fibroblasts. Note also the expanded stroma around the neoplastic cells, which is characteristic of the desmoplastic reaction. Scale bars, 200 µM. B. Quantification of immunohistochemistry results. Ten sections each of normal pancreatitis & adenocarcinoma specimens were stained with four different antibodies (622, COM, 1E6 & 4D10) & scored by two pathologists, as described in the text. Results for both ductal epithelium (left) & stroma (right) stained with various palladin antibodies are shown for normal pancreas (n = 9, blue), pancreatitis (n = 7, red) & pancreatic adenocarcinoma (n = 10, yellow). The results confirmed that palladin levels are increased in the stroma, & not the epithelial tumor cells, of the adenocarcinomas. Although palladin levels are also increased in cases of chronic pancreatitis, they do not reach the same levels as in the tumors. Compared to the polyclonal 622 & COM, the monoclonal antibodies 1E6 & 4D10 are effective at distinguishing between pancreatitis & cancer. C. Double-label immunostaining for palladin (1E6 Ab) & alpha-SMA in sections of pancreatic tumors confirms that palladin is strongly detected in a population of activated TAFs that surround the neoplastic cells. Scale bars, 200 µM. Image collected & cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0010347), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Palladin Antibody (1E6) [NBP1-25959] -

Western Blot: Palladin Antibody (1E6) [NBP1-25959] - Analysis of human palladin isoforms in pancreatic tissues.A. Human palladin isoforms. Proline-rich domains are represented by red boxes, & Ig-like domains are shown as blue boxes. The epitope recognized by the 1E6 & 4D10 antibodies is highlighted in green. The region amplified by RT-qPCR is highlighted in light blue. Isoform #1, 3 & 4 are the primary products of the palladin gene & have been detected by immunoblotting. The sequences of these isoforms are published. The sequences of isoforms #2, 5, 6, & 7 were obtained from genomic databases. “ND”: not-determined. B. Western blot analysis of pancreas samples. Small pieces of fresh tissue were snap-frozen in liquid nitrogen, ground in a chilled mortar & pestle, extracted in a detergent-containing lysis buffer, & centrifuged at 15,000×g to remove any unsolubilized particulates. The supernatant was boiled in Laemmli sample buffer & resolved by SDS-PAGE, with 15 µg protein loaded per lane. The samples were immunoblotted & probed with two anti-palladin antibodies & an antibody to GADPH (a housekeeping gene) as a control for equal loading. Lanes 1–2: normal pancreas. Lanes 3–5: primary adenocarcinoma tumors (PDA). Lane 6–7: Non-primary adenocarcinoma tumors (Non-PDA) (Lane 6: solid pseudopapillary tumor, Lane 7: neuroendocrine tumor). C. RT-qPCR. Total RNA was isolated from normal tissue (patients 1–4) & PDA tumors (patients 1–3), reverse transcribed, & subjected to RT-qPCR using gene-specific primers. Each bar represents the mean + SEM (0.06–0.35%) from three or more independent determinations. Image collected & cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0010347), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Palladin Antibody (1E6) [NBP1-25959] -

Western Blot: Palladin Antibody (1E6) [NBP1-25959] - Detection of palladin in post-surgical samples collected with 18-gauge needles.A. Samples of normal (lane 1 to 3) & pancreatic adenocarcinoma (lanes 4 to 7) were obtained from donated post-surgical organs using 18-gauge needles. Tissue samples were snap-frozen, ground, lysed & analyzed as in Figure 1. The blot was stained with both monoclonal (1E6) & polyclonal (622) palladin antibodies, & the major band (85–90 kDa) was detected by both antibodies in all tumor samples. B. Same samples (normal, lane 1–3 & PDA, lane 4–7) were analyzed for epithelial vs myofibroblast markers. The blot was stained with both, anti-E-cadherin antibody (as an epithelial cell marker) & anti-alpha SMA antibody (as a myofibroblast marker). Blots were stained for tubulin as a control for equal loading. Image collected & cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0010347), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Palladin Antibody (1E6) [NBP1-25959] -

Western Blot: Palladin Antibody (1E6) [NBP1-25959] - CAFs & NOFs are biochemically & morphologically different & CAF exosomes can also be transferred to CRC cells(A) Western blot of paired primary NOFs & CAFs for myofibroblastic markers alpha-smooth muscle actin ( alpha-SMA), fibronectin ED-A (ED-A FN1), palladin & vimentin. HSC-70 was used as an equal loading control. (B) Light microscopy of representative primary NOF & CAF cells (10x). (C) Fluorescence microscopy demonstrating phalloidin staining of F-actin filaments (green), counterstained with DAPI (blue; 40x). (D) Mean surface area & (E) intensity of phalloidin staining in a representative NOF-CAF pair. (F) Flow cytometry of DLD1 cells (control) & DLD1 cells co-cultured with CAF exosomes (exosome). The proportion of cells under the M1 region is given as a percentage. (G) Co-culture of CAF exosomes with DLD1 & SW480 cells with resultant increase in miR-199b & miR-21-5p. Data is presented as mean +/− SEM. Student's t-test (D, E) or paired t-test (F, G): *p<0.05, **p<0.01, ***p<0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29283887), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959] -

Immunocytochemistry/ Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959] - Effect of palladin depletion on terminal differentiation of C2C12 cells.(A) Phase contrast images of stable transfectants at late stages of differentiation. Scale bar is 50 μm. (B) Representative immunofluorescence images of stable transfectants at day 5 of differentiation. Cells were labeled with palladin (red), MyHC (green), & DAPI (blue). Scale bar is 100 μm. (C) Fusion index analysis of stable transfectants at day 5 (left) & day 7 (right) of differentiation. A minimum of 4,000 nuclei were counted from random fields of each cell line. Note that palladin depletion resulted in a decrease of the fusion index at the late stage of differentiation. (D) Quantification of multinucleated myotubes throughout the course of differentiation. (E) Quantification of the number of MyHC-positive cells in stable transfectants. All error bars indicate the means ± SD of at least four independent experiments. * indicates statistically significant difference from control cells, * p<0.05, ** p<0.01, *** p<0.001 by Student’s t-test. ns = not significant. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25875253), licensed under a CC-BY license. Not internally tested by Novus Biologicals.